Skip to main content
Premium Trial:

Request an Annual Quote

USPTO Publishes One Patent, Four Patent Applications Related to RNAi

Premium

Title: Inhibition of Hepatitis B Virus Replication by RNA Interference

Number: 7,067,249

Filed: May 19, 2004

Lead Inventor: Hsiang-Fu Kung, The Chinese University of Hong Kong

The invention, the patent's abstract states, "relates to the inhibition of hepatitis B virus replication by RNA molecules. … Specifically, the RNA molecules of the … invention are double-stranded ribonucleic acid molecules … [such as] small interfering RNAs, which are double-stranded RNAs that direct the sequence-specific degradation of messenger RNA in mammalian cells."

The abstract adds that the invention "relates to development of a new anti-HBV therapy by inhibition of hepatitis B virus replication using stably-expressed short hairpin RNAs, which degrade HBV pregenomic RNA and message RNAs. Included are methods of treatment of cancer by the administration of RNA molecules of the present invention in combination with surgery, alone or in further combination with standard and experimental chemotherapies, hormonal therapies, biological therapies/immunotherapies and/or radiation therapies."


Title: Double-Stranded Ribonucleic Acid Molecules Having Ribothymidine

Number: 20060142230

Filed: Sept. 2, 2005

Inventor: Steven Quay, Nastech Pharmaceuticals

"The invention relates to a double-stranded RNA molecule comprising between about 15 base pairs and about 40 base pairs, wherein at least one ribonucleotide of the dsRNA is a 5'-methyl-pyrimidine, and a method of using such modified dsRNA molecule to increase stability of RNA when in contact with a biological sample," the patent application's abstract states.


Title: Methods and Compositions Concerning siRNAs as Mediators of RNA Interference

Number: 20060142228

Filed: Dec. 23, 2004

Lead Inventor: Lance Ford, Ambion

According to the patent application's abstract, the invention "concerns an isolated siRNA of from about 5 to about 20 nucleotides that mediates RNA interference. Also disclosed are methods of reducing expression of a target gene in a cell comprising obtaining at least one siRNA of 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 basepairs in length; and delivering the siRNA into the cell. The siRNAs can be chemically synthesized RNA or an analog of a naturally occurring RNA."


Title: RNA Interference-Mediated Inhibition of Cholesteryl Ester Transfer Protein Gene Expression Using Short Interfering Nucleic Acid

Number: 20060142226

Filed: Aug. 19, 2004

Lead Inventor: Barry Polisky, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating cholesteryl ester transfer protein gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CETP gene expression and/or activity by RNA interference (RNAi) using small nucleic acid molecules."


Title: RNA Interference-Mediated Inhibition of Cyclin Dependent Kinase-2 Gene Expression Using Short Interfering Nucleic Acid

Number: 20060142225

Filed: June 30, 2004

Inventor: James McSwiggen, Sirna Therapeutics

"This invention relates to compounds, compositions, and methods useful for modulating cyclin dependent kinase-2 gene expression using short interfering nucleic acid molecules," the patent application's abstract states. "This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of CDK2 gene expression and/or activity by RNA interference using small nucleic acid molecules."

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.